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MaBACKGROUND Remote monitoring (RM) technology embedded within cardiac rhythm devices permits continuous
monitoring, which may result in improved patient outcomes.
OBJECTIVES This study used “big data” to assess whether RM is associated with improved survival and whether this is
inﬂuenced by the type of cardiac device and/or its degree of use.
METHODS We studied 269,471 consecutive U.S. patients implanted between 2008 and 2011 with pacemakers
(PMs), implantable cardioverter-deﬁbrillators (ICDs), or cardiac resynchronization therapy (CRT) with pacing capability
(CRT-P)/deﬁbrillation capability (CRT-D) with wireless RM. We analyzed weekly use and all-cause survival for each device
type by the percentage of time in RM (%TRM) stratiﬁed by age. Socioeconomic inﬂuences on %TRM were assessed
using 8 census variables from 2012.
RESULTS The group had implanted PMs (n ¼ 115,076; 43%), ICDs (n ¼ 85,014; 32%), CRT-D (n ¼ 61,475; 23%),
and CRT-P (n ¼ 7,906; 3%). When considered together, 127,706 patients (47%) used RM, of whom 67,920 (53%)
had $75%TRM (high %TRM) and 59,786 (47%) <75%TRM (low %TRM); 141,765 (53%) never used RM (RM None).
RM use was not affected by age or sex, but demonstrated wide geographic and socioeconomic variability. Survival
was better in high %TRM versus RM None (hazard ratio [HR]: 2.10; p < 0.001), in high %TRM versus low %TRM
(HR: 1.32; p < 0.001), and also in low %TRM versus RM None (HR: 1.58; p < 0.001). The same relationship was observed
when assessed by individual device type.
CONCLUSIONS RM is associated with improved survival, irrespective of device type (including PMs), but demonstrates
a graded relationship with the level of adherence. The results support the increased application of RM to improve patient
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ABBR EV I A T I ON S
AND ACRONYMS
CI = conﬁdence interval
CIED = cardiac electronic
implantable device
CRT = cardiac
resynchronization therapy
CRT-D = cardiac
resynchronization therapy with
deﬁbrillation capability
CRT-P = cardiac
resynchronization therapy with
pacing capability
HR = hazard ratio
ICD = implantable
cardioverter-deﬁbrillator
MIR = mortality incidence rate
MIRR = mortality incidence
rate ratio
PM = pacemaker
RM = remote monitoring
RM None = never used
remote monitoring
TRM = time in remote
monitoring
%TRM = percentage of time in
remote monitoring
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2602schedule (4,6,10). However, whether these
actions have a tangible effect on patient
outcome remains an area of active investiga-
tion. First reports from studies using high-
voltage CIEDs indicated improved survival
among patients assigned to remote manage-
ment in both an observational cohort (ALTI-
TUDE) (11) and the randomized IN-TIME
(Inﬂuence of Home Monitoring on Mortality
and Morbidity in Heart Failure Patients with
Impaired Left Ventricular Function) trial (5).
Mechanisms remain unclear, but facilitation
of ventricular arrhythmia/shock manage-
ment has been proposed as one explanation.SEE PAGE 2611To better understand the inﬂuence of RM
on outcomes, we hypothesized that survival
would be better in patients with greater RM
use and should apply to all types of CIEDs:
patients with pacemakers (PMs) who have
less cardiovascular risk as well as those with
implantable cardioverter-deﬁbrillators (ICDs)
and cardiac resynchronization therapy (CRT)
with pacing/deﬁbrillation capability (CRT-P/
CRT-D). We tested this in a cohort of CIEDpatients, all receiving automatic RM devices, by
leveraging “big data” from a nationwide RM system-
generated proprietary database, which collects
comprehensive longitudinal follow-up data in hun-
dreds of thousands of patients.
METHODS
STUDY DESIGN AND PATIENT SELECTION. This
retrospective, national, observational cohort study
evaluated 371,217 consecutive patients receiving new
implants of market-released PMs, ICDs, CRT-Ps, and
CRT-Ds (St. Jude Medical, Inc., Sylmar, California). To
assess the impact of RM use on outcome, patients
whose implanted device did not support automatic
daily monitoring were excluded (deemed not auto-
matic RM capable) (Figure 1). The remaining patients
with ICD/CRT-D devices implanted between October
2008 and December 2011 and PM/CRT-P devices
implanted between October 2009 and December 2011
comprised the study cohort (automatic RM capable).
Patients enrolled in another clinical trial or with
follow-up time <90 days also were excluded.
Included patients were followed until death or device
replacement/removal through November 2013.
Study data were obtained from 4 sources: device
implant registration, device RM, postal (ZIP) code
sociodemographic data, and the U.S. Social SecurityDeath Master File. Age, sex, device type, and follow-
up duration were ascertained using manufacturer
device tracking data. Remote monitoring status was
determined from the Merlin patient care network
(St. Jude Medical) and date of death from the U.S.
Social Security Death Master File, with all death re-
cords through November 30, 2013. We added death
reports through this date made directly to the device
manufacturer’s U.S. tracking system by health care
providers or family members (this accounted for <1%
of deaths). Socioeconomic data were gathered from
the 2012 U.S. Census Bureau American Community
Survey, 2008 to 2012, by individual ZIP code tabula-
tion area, speciﬁcally, 4-year college degree, median
income, below poverty level, telephone or cell phone
service, employment status, health care insurance,
and total urban/rural classiﬁcation of population
counts (12). The urban percentage for a region was
computed as the ratio of urban to total population
counts. We obtained data without patient identiﬁers
from implant registration records of devices manu-
factured by St. Jude Medical, Inc. Data included date
of implantation, age at implantation, sex, patient ZIP
code, site ZIP code, and device model numbers. For
patients enrolled in the Merlin patient care network
remote monitoring, we obtained data without patient
identiﬁers consisting of maintenance transmission
dates linked to implant registration data.
Among RM-capable patients, RM service use was
computed using weekly status data sent from each
user of Merlin to the central server. A multiple-retry
algorithm ensured the status data were communi-
cated when an attempt to send data to the server
failed. Those patients having had at least 1 trans-
mission ever were classed as RM Any. RM adherence
per patient was deﬁned as the proportion of total
follow-up weeks having at least 1 status transmission
or percentage of time in RM (%TRM). To determine
whether %TRM affected outcome, RM-capable pa-
tients were assigned to 1 of 3 groups based on extent of
their RM use. Those with 0%TRM were designated as
RM None. RM Any patients were further divided into
high %TRM or low %TRM groups by a cut point of 75%
use (this value approximated median %TRM) Thus,
low %TRM patients were those sending weekly main-
tenance records to the server <75% (but >0%) of their
follow-up time in this study, whereas high %TRM pa-
tients were those who sent weekly maintenances re-
cord to the server $75% of their follow-up time.
STATISTICAL ANALYSIS. The primary endpoint of
this study was all-cause mortality, which was deter-
mined using unadjusted mortality incidence rates
(MIRs) and adjusted survival via Cox proportional
hazards survival models. The MIR ratio (MIRR), RM
FIGURE 1 Study Design
CIEDs
N = 371,217
Source
Cohort
Time
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Adherence
Outcomes
Automatic RM Capable
N = 269,471
ICD/CRT-D Implants
Implant Oct 2008
to Nov 2011
Follow-up to Nov 2013
N = 269,471
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(%TRM > 0)
High %TRM
N = 67,920
25%
Low %TRM
N = 59,786
22%
Mortality
RM None
N = 141,765
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PM/CRT-P Implants
Implant Oct 2009
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Not Automatic RM
Capable
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Only patients receiving devices embedded with the ability for automatic daily remote
monitoring (RM) were evaluated (Automatic RM Capable), categorized by the degree of RM
use: high %TRM ($75%), low %TRM (0% to 75%), and those who never used RM (RM
None). (Patients with devices not equipped with radiofrequency antennae and those using
wanded telemetry were excluded [Not Automatic RM Capable]). %TRM ¼ percentage of
time in remote monitoring; CIEDs ¼ cardiac electronic implantable devices; CRT-D, cardiac
resynchronization therapy with deﬁbrillation capability; CRT-P, cardiac resynchronization
therapy with pacing capability; ICD ¼ implantable cardioverter-deﬁbrillator; PM ¼
pacemaker.
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determined from the patient deaths, and the follow-up
duration determined for patients in each group. All-
cause survival was compared for each device type
among patients with high %TRM, low %TRM, and RM
None using multivariable Cox proportional hazards
modeling with stratiﬁcation based on age and cova-
riates of sex plus the RM predictor census variables.
The Cox proportional hazard ratio (HR) and 95% CI
were determined. Length of follow-up was calculated
for each patient as the time from device implantation
until device explantation, replacement, death, or end
of study surveillance. To assess socioeconomic in-
ﬂuences on %TRM, the 8 census variables were eval-
uated between high %TRM and low %TRM using
logistic regression and stepwise backward elimination
for p values <0.2. These variables were then used for
adjustment in the Cox survival regression.
All statistical analyses were performed with
Revolution R Enterprise 7.1.0 (Revolution Analytics,
Mountain View, California). Patient demographics
were assessed as mean  SD, median (interquartile
range), or n (%). The Student t test was used to
determine the p value for mean comparison and the
chi-square test for the p value for count.
To assess the geographic distribution of RM use
across the United States, a 2-dimensional clustering
of RM Any patients was performed based on latitude
and longitude from the 3-digit ZIP code. For low-
density regions, additional aggregation was per-
formed using a nearest-neighbor method to combine
adjacent ZIP codes until a minimum of 100 patients
per geographic grouping was obtained. The groups
were then merged, and the center of the combined
group was determined as the weighted average of the
latitude and longitude for the combined group. All
resulting geographic groups were divided into tertiles
based on the mean %TRM in each group.
RESULTS
From the initial 371,217 patients, 101,746 whose de-
vices were not RM capable were excluded (Figure 1).
The study cohort consisted of 269,471 automatic RM
capable patients (age, 71.0  13.5 years; 64.8% male)
with a mean follow-up of 2.9  1.0 years (Table 1).
Missing ZIP code data accounted for <0.1% (1,694) of
patients for whom missing values were imputed from
the median value for the state of residence.
Overall, 141,765 (53%) patients with automatic RM-
capable devices never used RM (RM None). Among
those patients using RM (RM Any; n ¼ 127,706), dis-
tribution of use was skewed (Central Illustration, top),
but 90,087 patients (70.6%) used RM $50% of thetime. Dichotomization by a 75% use value (close to the
median) divided RM Any into relatively balanced pa-
tient populations of high %TRM (n ¼ 67,920 [53.1%])
and low%TRM (n¼ 59,786 [46.9%]). Thus, high %TRM
comprised 25.2% (67,920 of 269,471) of all automatic
RM capable patients. The median (interquartile range)
time to initiation of RM from device implantation was
12 (4 to 33) weeks for RM Any, 33 (11 to 74) weeks for
low %TRM, and 6 (3 to 15) weeks for high %TRM.
MORTALITY AND SURVIVAL RESULTS. Overall, sur-
vival was greater in those patients with some %TRM
TABLE 1 Patient Demographic Characteristics
Parameter
All
(N ¼ 269,471)
RM None*
(n ¼ 141,765)
RM Any*
(n ¼ 127,706) p Value
Follow-up, yrs 2.9  1.0 2.8  1.1 3.0  1.0 <0.001
Age, yrs 71.0  13.5 70.8  14.0 71.1  12.9 <0.001
Male 174,553 (64.8) 92,103 (65.0) 82,450 (64.6) 0.028
Device type
ICD 85,014 (31.6) 45,232 (31.9) 39,782 (31.2) <0.001
PM 115,076 (42.7) 60,494 (42.7) 54,582 (42.7) <0.001
CRT† 69,381 (25.8) 36,039 (25.4) 33,342 (26.1) <0.001
Remote monitoring
RM use, % NA NA 78.1 (41.6–92.9)
First RM transmission, weeks NA NA 12 (4–33)
Last RM transmission, weeks NA NA 1 (1–10)
ZIP code–linked data‡
Bachelor’s degree 26.2  15.1 26.1  15.1 26.3  15.1 0.023
Median income 54.6  21.8 54.3  22.1 54.9  21.4 <0.001
Below poverty line 14.1  8.4 14.6  8.8 13.4  7.8 <0.001
Have telephone 97.5  2.3 97.4  2.5 97.6  2.1 <0.001
Receive SNAP 1.1  1.1 1.2  1.1 1.1  1.1 <0.001
Uninsured 14.6  7.5 15.2  7.9 13.9  6.9 <0.001
Residence: urban 76.3  33.4 79.4  21.5 72.4  35.1 <0.001
Not in labor force 37.4  8.9 37.5  8.9 37.4  9.0 <0.001
Unemployed 9.7  4.4 10.1  4.5 9.3  4.2 <0.001
Values are mean  SD, n (%), or median (interquartile range). *For some parameters, comparison between RM
Any and RM None yields differences that are very small in magnitude but statistically signiﬁcant. This is due to
the huge number of patients in each group, for whom even a small difference between largely similar populations
becomes signiﬁcant statistically. †CRT included CRT-D (n ¼ 61,475; 23% total) and CRT-P (n ¼ 7,906; 3% total)
devices. ‡All parameters in this section were measured as % in ZIP code except median income, which was
thousands of dollars in ZIP code.
CRT ¼ cardiac resynchronization therapy; CRT-D ¼ cardiac resynchronization therapy with deﬁbrillation
capability; CRT-P ¼ cardiac resynchronization therapy with pacing capability; ICD ¼ implantable cardioverter-
deﬁbrillator; NA ¼ not available; PM ¼ pacemaker; RM ¼ remote monitoring; RM Any ¼ remote monitoring
used at least once; RM None ¼ no remote monitoring use; SNAP ¼ Supplemental Nutrition Assistance Program.
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(Table 2). This relationship existed in all CIED cate-
gories, including PMs. The MIRR for RM Any versus
RM None was #0.55 across all CIED devices, demon-
strating that patients using RM have substantially
decreased mortality. The Central Illustration shows
that for all devices, patients with high %TRM had a
lower MIR (MIR: 3,083 of 6,330 deaths per 100,000
patient-years; MIRR: 0.49) and greater survival than
RM None (adjusted HR: 2.10; 95% CI: 2.04 to 2.16;
p < 0.001). Signiﬁcantly, patients with low %TRM also
had lower mortality (MIR: 3,865 of 6,330; MIRR: 0.61)
and greater survival than patients with RM None
(adjusted HR: 1.58; 95% CI: 1.54 to 1.62; p < 0.001).
Patients with high %TRM had lower mortality than
those with low %TRM (adjusted HR: 1.32; 95% CI: 1.27
to 1.36; p < 0.001). (These differences remained un-
changed whether 75% use or median [78.1%] was used
as a cut point to split RM Any into high %TRM and low
%TRM groups.) These observations indicate a gradient
between the relationship of RM use and outcome.
These relationships were explored further accord-
ing to individual device types. Results are depicted inFigure 2 with HR and p value. Overall, outcomes were
superior in high %TRM and low %TRM compared
with RM None for all device types including PMs.
Outcomes were also better in high %TRM compared
to low%TRM, except for CRT-P, likely due to the much
smaller number of patients studied. Because the trend
was directionally consistent with CRT-D (and other
groups) (Table 2), we anticipate that a larger study
population and/or longer follow-up may reveal a
signiﬁcant difference between these 2 categories for
CRT-P.
SOCIOECONOMIC ANALYSIS. All 8 socioeconomic
variables linked by ZIP code to the patients in this
study were found to be statistically signiﬁcant in
predicting degree of RM use (high %TRM or low
%TRM), but the magnitude of the associations was
insubstantial. A landline phone or cell phone in the
home and completion of at least 4 years of college
were positive predictors of RM use. Living below the
poverty line, lacking health insurance, unemployed,
not in the work force, lower median income, and
living in an urban neighborhood predicted less
RM use (all p < 0.001). Neither age nor sex affected
RM use substantially (RM None vs. RM Any: 70.8 vs.
71.1 years; 65.0% female vs. 64.6% male). (Note that
the economic status and education of the speciﬁc
patients were not known: this was simply an analysis
of ZIP code–associated data).
The geographic distribution of %TRM is shown in
tertiles of use (Figure 3). The apparent scarcity of
patients in the High Plains and Intermountain West is
due to aggregation of data to maintain patient pri-
vacy. There are fewer patients in that region, but they
are more dispersed than suggested by this projection.
There is wide geographic and socioeconomic vari-
ability in the degree of RM use nationally, with a
small but statistically signiﬁcant bias toward rural
residence for high %TRM patients.
DISCUSSION
In this nationwide comparative effectiveness study of
RM use in more than 269,000 patients with implanted
CIEDs, there are 3 main ﬁndings. First, RM use was
associated with improved survival. Second, the de-
gree of adherence to remote management correlated
strikingly with the magnitude of survival gain, sug-
gesting a gradient of effect. Thus, patients with high
%TRM ($75%) exhibited the best survival, but those
with low %TRM still had markedly better survival
compared with patients not using RM at all. For all
devices, the MIR (per 100,000 patient-years) was
3,083 for high %TRM, 3,865 for low %TRM, and 6,330
for RM None (p < 0.001). Finally, the association
CENTRAL ILLUSTRATION Remote Monitoring Use and Impact
Varma, N. et al. J Am Coll Cardiol. 2015; 65(24):2601–10.
Remote monitoring (RM) technology embedded in cardiac rhythm devices enables continuous monitoring, but the degree of automaticity (i.e.,
requirement for active patient participation in using this service) varies. In this study, RM was not used in 53% of patients (RM None) (top).
Among those patients using RM at least once (RM Any), median RM use was 78.1% (range, 41.6 to 92.9). In this group, the number of patients
according to adherence level (%) was >0% to <25%, 20,796; $25% to <50%,16,823; $50% to <75%, 22,167; and $75% to #100%,
67,920. RM use was divided by a 75% cut point into high %TRM ($75% use) and low %TRM (<75% use). Greater RM use demonstrably
improved patient survival for all devices (bottom). In summary, patients who never used RM (RM None) and low %TRM accounted for 74.7%
of all patients; hence, only one-fourth of the U.S. population receiving an automatic RM-capable device maximize its usefulness.
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TABLE 2 Mortality, MIR, and MIRR
Device n Deaths RM Any (%)
MIR
(per 100,000 pt-yr)
RM None
(95% CI)
RM Any
(95% CI) MIRR
All 269,471 38,130 (4.9) 47.4 6,329.9 (6,252.0–6,408.8) 3,457.0 (3,398.2–3,516.7) 0.55
PM 115,076 13,256 (4.2) 47.4 5,364.5 (5,252.8–5,478.6) 3,016.7 (2,930.7–3,105.3) 0.56
CRT-P 7,906 1,345 (6.6) 45.9 8,612.0 (8,070.1–9,190.9) 4,501.7 (4,099.3–4,944.2) 0.52
ICD 85,014 11,652 (4.5) 46.8 5,816.9 (5,689.5–5,947.1) 3,019.7 (2,925.4–3,117.00) 0.52
CRT-D 61,475 11,877 (6.6) 48.3 8,592.8 (8,402.3–8,787.7) 4,698.4 (4,559.1–4,842.0) 0.55
Values are n (% per pt-yr) unless otherwise indicated.
CI ¼ conﬁdence interval; MIR ¼ mortality incidence rate; MIRR ¼ mortality incidence rate ratio; pt-yr ¼ patient-year; other abbreviations as in Table 1.
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patients receiving CIEDs, including CRT-D, ICD,
and, importantly, PMs. These associations were not
altered substantively by age, sex, or socioeconomic
variations. Remarkably, only one-fourth of all patients
receiving automatic RM–capable CIEDs in this nation-
wide analysis were in the high %TRM category, indi-
cating that the vast majority of recipients do not use
the full capabilities of their implantable devices.
The ALTITUDE observational study in patients with
ICDs and CRT-Ds reported improved survival in pa-
tients assigned to remote management compared with
those without (11). Our results are important for not
only conﬁrming this association in a larger patient
cohort and with a separate proprietary remote tech-
nology, but also for extending this to analysis of PMs
and to testing the effect of differing levels of RM use.
Furthermore, an ALTITUDE substudy analysis recog-
nized that physician and hospital factors determined a
lack of patient enrollment in RM. In these patients,
other practice constraints and lower adherence to
other recommended treatments possibly may have
contributed to poorer patient outcome (13). (A review
of CIED follow-up practice among U.S. Medicare bene-
ﬁciaries from 2005 to 2008 revealed that patient
survival was diminished among patients with
infrequent post-CIED follow-up [14]). Unlike the
ALTITUDE study, we restricted our analysis to only
patients who received devices capable of automatic
RM, thereby eliminating at least 1 level of selection
bias. Hence, our results showing the correlation of RM
with survival gain and its modulation by degree of use
are unlikely to be due to systematic differences in RM
availability.
An important discovery in our study is that the
strong association between RM and improved survival
extended to patients with PMs who typically do not
have left ventricular dysfunction or heart failure.
Consistent with this “lower risk,” PM patients in ouranalysis exhibited the best survival among the CIED
groups tested, with or without RM (Table 2). This
suggests that RM has advantages in patients regard-
less of their susceptibility to ventricular arrhythmias
and/or shock therapies, which were considered factors
contributing to results in the ALTITUDE study. Iden-
tiﬁcation of atrial arrhythmias, high-rate episodes,
and changes in pacing and lead parameters may all
represent potential actionable ﬁndings in patients
with PMs (9). Earlier intervention for these problems
may lead to improved outcomes. This hypothesis was
supported by the results of the COMPAS (Comparative
Follow-up Schedule with Home Monitoring) random-
ized clinical trial, although the study was not sufﬁ-
ciently powered to evaluate survival (15).
The current results illustrate the critical impact of
adherence. To beneﬁt from RM, patients (and pro-
viders) must use it. Earlier activation and then main-
tenance of consistent transmissions were associated
with the best outcomes. The demonstration of a
graded effect of RM use on outcome extends the value
of an observational analysis beyond that of previous
work that simply compared effects of RM on or off
(12,13). In support of a direct RM effect, our results for
high %TRM parallel the degree of survival beneﬁt
noted among heart failure patients treated with ICDs
and CRT randomized to RM with a different pro-
prietary technology (Home Monitoring, Biotronik,
Berlin, Germany) when a consistently high (85%) level
of connection was ensured (5). Nevertheless, here we
demonstrated that patients maintaining some level
of connectivity, although gaining less beneﬁt, still
derived some survival advantage comparedwith those
not using RM at all. This relationship is analogous to
the achievement of therapeutic anticoagulation in
patients with atrial ﬁbrillation: %TRM may be as
important for device patients as the time in thera-
peutic range is for patients with atrial ﬁbrillation
taking warfarin.
FIGURE 2 Kaplan-Meier Survival Curves
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High %TRM patients (orange line) consistently have higher survival curves compared with low %TRM (green line) and RM None patients
(blue line) for pacemakers (A), ICDs (B), CRT-P devices (C), and CRT-D devices (D). HR ¼ hazard ratio; other abbreviations as in Figure 1.
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2607RM in isolation is not a treatment but a mechanism
for accessing important data regarding device func-
tion or incipient clinical conditions. Alerts that drive
urgent in-person evaluation carry a high probability
of actionability for reprogramming and/or changes
in drug therapy, either of which has the potential
to improve outcome (4,10). However, physicianresponses are unavailable given the nature of the
current study. Several interdependent cardiovascular
factors (e.g., arrhythmias, shifts in right ventricular/
biventricular pacing burden, vagal withdrawal, de-
creased patient activity) may change several days to
weeks before clinical deterioration (16,17), permitting
provider intervention based on RM data upstream
FIGURE 3 U.S. Geographic RM Distribution
Continental United States
Legend
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Geographic Distribution of Remote Monitoring
A clear geographic pattern emerges with regard to RM in the United States as seen both in tertiles of %TRM: high (green) (mean %TRM$72%),
moderate (yellow) (mean %TRM 21% to <72%), and low (red) (mean %TRM <21%), and according to the density of the RM population, from
high density (large circles ¼ population $2,000) to low density (small circles ¼ population <200). Abbreviations as in Figure 1.
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2608of clinical symptoms. Optimized management of clin-
ical conditions and/or device function may underlie
the survival advantage among remotely managed
patients (5,16,17).
Our observational study cannot conﬁrm a di-
rect cause-and-effect relationship between RM and
survival, although alignment of the described mor-
tality effect with that in a smaller numbers of patients
managed remotely in randomized trials may point
to such an effect (5). Association may be attributed
to a “healthy-user effect,” that is, patients who use
RM more are less sick and more compliant in general
and/or have physicians who are more up to date with
recommended treatment. An ALTITUDE subanalysis
indicated that both implantation of an RM-capable
device and patient activation were diminished in
patients with disadvantaged socioeconomic status
and/or greater comorbidities (13). However, account-
ing for 17 such factors generated a modest area under
the curve of only 0.62, meaning this “risk-treatment
paradox” was an incomplete explanation of the RM
effect.In this regard, our observations in low-voltage
CIED categories are salient: a similar increment in
survival gained by high adherence in both PM and
CRT-D patients supports an effect of RM use that is
independent of the gravity of underlying cardiac
disease and associated comorbidities. The similar
gain among different CIED categories also indicates
that the RM effect is independent of the degree of
programming versatility or therapeutic potential of
the CIED itself (greatest in CRT-D, least in PMs).
Notably, the TRUST (Lumos-T Safely RedUceS
Routine Ofﬁce Device Follow-up) trial demonstrated
that use of RM itself facilitated patient compliance
because randomization to RM promoted patient
engagement with follow-up services (18). A similar
effect was observed in follow-up clinics: randomiza-
tion to RM improved patient retention to long-term
follow-up (18,19). Collectively, these actions (to
“induce” a positive behavioral change) may improve
initiation and maintenance of recommended treat-
ments (e.g., medications), extending effects beyond
device management. These actions may account for
PERSPECTIVES
COMPETENCY IN PATIENT CARE: RM technology embedded
in cardiac rhythm devices enables close follow-up of patients
after implantation and is associated with improved clinical
outcomes proportionate to adherence to periodic data
transmissions.
TRANSLATIONAL OUTLOOK: Understanding the mecha-
nisms by which RM confers survival beneﬁt and the factors
responsible for patient nonadherence to RM are important
objectives for future investigations.
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2609the graded relationship between RM use and survival
noted here. Clearly, the beneﬁt of RM is multifacto-
rial. This may explain why no single intervention
leading to a clear-cut mortality beneﬁt was isolated
in the IN-TIME trial. In this regard, our nationwide
“big data” analysis is more likely to discover and
conﬁrm the total result of interconnected factors
than a randomized trial with a narrow ﬁeld of view
(20,21).
STUDY LIMITATIONS. Our results apply to implant-
able units enabled with automatic remote trans-
mission technology and cannot be extended to other
remote management systems. In particular, non-
implantable RM systems (characterized by modest
adherence) have failed to improve patient outcomes
(22). Causes of discontinuation or lost transmission in
the current study cannot be ascertained. Although
socioeconomic factors signiﬁcantly affected connec-
tivity, the magnitude of this association was slight
and insufﬁcient to affect outcomes. Inclusion of
earlier versions of RM technology demanding greater
patient participation are more vulnerable to trans-
mission loss (23). Change of residence may account
for some attrition (19). Our study period commenced
after publication of recommendations for CIED
follow-up describing the role of RM as an adjunctive
mechanism to in-person evaluation, without advo-
cating for continuous monitoring functions (2). This
may have contributed to variable connectivity among
our patients. Clinical proﬁles beyond age and sex
were unavailable. Demographic characteristics, med-
ications, etiology of heart failure and left ventricular
function, comorbidities, heart failure hospitaliza-
tions, and, importantly, individual responses to
remotely acquired data may all affect mortality. This
study was not a randomized clinical trial and there-
fore cannot comment on efﬁcacy. However, although
lacking access to detailed clinical data, this analysis
reports outcomes from consecutive patients in a
nationwide clinical practice, and, as such, the data
are generalizable as opposed to the highly controlled,
selected, and relatively small populations studied in
clinical trials (20,21).CONCLUSIONS
RM of patients with cardiovascular disease receiving
all types of CIEDs (including PMs) is associated with
improved all-cause survival, but maximal gain de-
pends on earlier implementation and consistent
adherence. Although our observational study cannot
determine a cause-and-effect relationship, the re-
striction of our analysis to only patients receiving
wireless RM, the correlation with survival to the de-
gree of use, and similar gains irrespective of device
type among patients with differing gravity of under-
lying disease provide strong indirect evidence of an
independent inﬂuence of RM on patient outcome.
Our ﬁndings endorse recommendations advocating
the importance of post-implantation CIED follow-up,
but also support extension of function from a peri-
odic remote interrogation mechanism to a daily
monitoring system enabling improved outcome (2,7).
This result has a potential impact on millions of in-
dividuals with implanted devices worldwide.
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